Momenta Pharmaceuticals Inc (MNTA)

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

In trading on Tuesday, shares of Momenta Pharmaceuticals Inc crossed above their 200 day moving average of $13.55, changing hands as high as $13.80 per share. Momenta Pharmaceuticals Inc shares are currently trading up about 3% on the day.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

In trading on Tuesday, shares of Momenta Pharmaceuticals Inc crossed below their 200 day moving average of $13.28, changing hands as low as $13.18 per share. Momenta Pharmaceuticals Inc shares are currently trading off about 5.4% on the day.

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Momenta Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.